FDA Approves Darolutamide for Metastatic Castration-Sensitive Prostate Cancer By Ogkologos - June 27, 2025 457 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the ARANOTE study Source RELATED ARTICLESMORE FROM AUTHOR Treatment with Encorafenib Plus Cetuximab Plus FOLFIRI Improves Outcomes in Patients with BRAF V600E-mutated mCRC FDA Approves Belzutifan with Pembrolizumab for Adjuvant Treatment of Renal Cell Carcinoma How Decades of NCI Support Led to Groundbreaking Discoveries: The Story of Immune Checkpoint Inhibitors MOST POPULAR Telehealth Can Save People with Cancer Time, Travel, and Money February 16, 2023 ESMO Breast Cancer 2025, Munich, Germany, 14-17 May 2025 May 7, 2025 Neoadjuvant Pembrolizumab Associated with Limited Side Effects and High Clinical Activity... January 16, 2023 Jimmy Carter Signed This Treaty Demanding An End To Violence Against... May 7, 2021 Load more HOT NEWS EMA Recommends Granting a Marketing Authorisation for Lutetium (177lu) Chloride Electronic Symptom Monitoring with PROs Improves Patient-Reported Physical Function, Symptom Control,... Opinion: ‘Beating cancer means beating it for everyone’ Inpatient Mammography May Help Solve Issue of Low Screening Rates, Especially...
